ASX Share rice
Fri 14 May 2021 - 07:19:pm (Sydney)

DXB Share Price

DIMERIX LIMITEDDXBPharmaceuticals, Biotechnology & Life Sciences

DXB Company Information

Name:

Dimerix Limited

Sector:

Healthcare

Industry:

Biotechnology

GIC Industry:

Biotechnology

GIC Sub Industry:

Biotechnology

Address:

425 Smith Street Fitzroy VIC Australia 3065

Phone:

61 3 0081 3321

Exec. Chairman:

Dr. James Howard Williams M.B.A., BSc (Hons), Ph.D., MBA, GAICD

CEO, MD & Director:

Dr. Nina Webster Ph.D., M.IP.Law, MBA

CFO & Company Sec.:

Mr. Hamish George B.Com., C.A.

Chief Scientific Advisor:

Mr. Kevin Donald George Pfleger BA (Hons), MA, Ph.D.

Bus. Devel. Officer:

Ms. Elizabeth McCall B.Com., L.L.B., LLB., B.Juris, B.Com(Hons), GAICD

Company Overview:

Dimerix Limited, a biotechnology company, develops and commercializes new therapies in the area of unmet medical needs. It offers DMX-200, which is in Phase II clinical trial for the treatment of diabetic kidney diseases and focal segmental glomerulosclerosis; and DMX-700, which is in pre-clinical stage for the treatment of chronic obstructive pulmonary disease, as well as proprietary ReceptorHIT assay technology. The company was incorporated in 1975 and is headquartered in Fitzroy, Australia.

DXB Share Price Information

Shares Issued:

198M

Market Capitalisation:

$51.48M

Revenue (TTM):

$2.47M

Revenue Per Share (TTM):

$0.01

Earnings per Share:

$-0.018

Profit Margin:

-2.2344

Operating Margin (TTM):

$-2.27

Return On Assets (TTM):

$-0.77

Return On Equity (TTM):

$-1.58

Quarterly Revenue Growth (YOY):

72.443

Gross Profit(TTM):

$2.34M

Diluted Earnings Per Share (TTM):

$-0.029

DXB CashFlow Statement

CashFlow Date:

2020-06-30

Change To Liabilities:

$786.08K

Net Borrowings:

$1.01M

Net Income:

$-4,494,153

Total Cash From Operating Activities:

$-4,721,480

Depreciation:

$13.53K

Change To Account Receivables:

$-1,189,115

Sale Purchase Of Stock:

$8.34M

Capital Expenditures:

$0

DXB Income Statement

Income Date:

2020-06-30

Income Before Tax:

$-4,494,150

Net Income:

$-4,494,150

Operating Income:

$-4,494,150

Total Revenue:

$2.70K

DXB Balance Sheet

Balance Sheet Date:

2020-06-30

Total Liabilities:

$2.63M

Total Stockholder Equity:

$7.76M

Total Assets:

$10.39M

Common Stock:

$28.34M

Other Current Assets:

$30.35K

Retained Earnings:

$-21,435,833

Cash:

$7.79M

Total Current Liabilities:

$2.63M

Short-Term Debt:

$1.06M

Property - Plant & Equipment:

$1.23K

Net Tangible Assets:

$7.76M

Total Current Assets:

$10.39M

Net Receivables:

$2.46M

Short-Term Investments:

$1.23K

Accounts Payable:

$1.15M

Short-Term Investments:

$1.23

Non Current Liabilities Total:

$0

DXB Share Price History

DXB News

01 Feb, 2021
Nina Webster has been the CEO of Dimerix Limited ( ASX:DXB ) since 2018, and this article will examine the executive's...
29 Jul, 2020
Dimerix reported excellent results from the clinical trial of drug DMX-200 aimed at rare kidney disease focal segmental glomerulosclerosis (FSGS)